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Tbjective: Residual clot strands within the excised saphenous vein are an increas-
ngly recognized sequela of endoscopic vein harvest. We hypothesized that endo-
copic visualization facilitated by sealed carbon dioxide insufflation causes stagna-
ion of blood within the saphenous vein. In the absence of prior heparin
dministration, this stasis provokes clot formation.
ethods: Forty consecutive patients having coronary artery bypass grafting under-
ent endoscopic vein harvest using sealed (Guidant VasoView, n  30; Guidant
orp, Minneapolis, Minn) or open (Datascope ClearGlide, n 10; Datascope Corp,
ontvale, NJ) carbon dioxide insufflation followed by ex vivo assessment of
ntraluminal saphenous vein clot via optical coherence tomography. In the sealed
arbon dioxide insufflation groups, clot formation was compared with (prehepa-
inized, n  20) and without (control, n  10) heparin administration before
ndoscopic vein harvest, either at a fixed dose or titrated to an activated clotting time
reater than 300 seconds. Risk factors for clot formation were assessed.
esults: Residual saphenous vein clot was a universal finding in control veins
sealed carbon dioxide insufflation endoscopic vein harvest without prehepariniza-
ion). At either dose used, heparin given before endoscopic vein harvest significantly
ecreased saphenous vein clot burden. A similar reduction in clot was observed
hen using open carbon dioxide insufflation endoscopic vein harvest without
reheparinization. Intraoperative blood loss and blood product requirements were
imilar in all groups. Patient age and preoperative maximum amplitude of the
hrombelastography tracing showed a linear correlation with saphenous vein clot
olume.
onclusion: By enabling the quantification of this issue as never before possible,
ptical coherence tomography screening revealed that intraluminal saphenous vein
lot is frequently found after endoscopic vein harvest. Systemic heparinization
efore harvest or an open carbon dioxide endoscopic vein harvest system are benign
hanges in practice that can significantly lessen this complication.
he saphenous vein graft (SVG) remains the most commonly used surgical
conduit in coronary artery bypass grafting (CABG) (Society of Thoracic
Surgeons National Cardiac Database). Endoscopic vein harvest (EVH) has
een rapidly adopted and is now used in 80% of cardiac surgery centers owing to
ramatic improvements in wound morbidity and cosmesis compared with traditional
pen methods.1-3 A recent meta-analysis of randomized clinical trials found no
dverse effect of endoscopic harvest on SVG patency.4 However, the studies
ncluded in this analysis enrolled small numbers of patients and used variable
anagement protocols and EVH systems. More recently, the PREVENT IV mul-icenter CABG trial assessed 12-month patency in more than 4000 SVGs and found
he Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 5 1259
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EThe use of EVH to be an independent predictor of graft
ailure as compared with open harvest (odds ratio  1.35,
 .001).5
It is not clear how EVH might increase the risk of SVG
oss. Prior studies,2,6 including one from our own group,7
ave reported no significant differences in intimal trauma
or veins harvested via endoscopic versus open techniques.
owever, the presence of retained clot within the saphenous
ein (SV) lumen has been an increasingly recognized com-
lication of EVH.8 An intravascular imaging modality
nown as optical coherence tomography (OCT) provides a
ovel means for intraoperative assessment of the entire tract
f harvested SV and thereby allows for the quantification of
ntraluminal clot burden.9 We hypothesized that carbon
ioxide (CO2) insufflation within a closed tunnel around the
V, used to facilitate endoscopic visualization, causes stag-
ation of blood that leads to clot strand formation. The
urpose of this study was to test this hypothesis by com-
aring clot burden defined by OCT after two different
odifications to our current practice: (1) with and without
eparin anticoagulation given before EVH initiation and (2)
ith the use of two different EVH devices that do and do
ot allow blood flow to be maintained in the SV during
arvest (ie, open versus sealed CO2 insufflation).
aterials and Methods
atient Enrollment and Data Management
fter Institutional Review Board approval (University of Mary-
and, Baltimore, protocol 25350), 40 consecutive subjects sched-
led for CABG with an SVG were enrolled. The first 10 patients
ere treated according to the standard of care at our institution:
VH using a sealed and constant method of CO2 insufflation
VasoView6; Guidant Corp, Minneapolis, Minn) without prior
nticoagulation (control). An additional 20 patients in whom the
asoView EVH system was used received systemic heparin anti-
oagulation before the initiation of EVH, either titrated to an
ctivated clotting time greater than 300 seconds (n  10) or as a
ingle 5000-IU intravenous bolus (n  10). The last 10 subjects
nderwent SV harvest without prior heparinization using an “open
O2” EVH system (ClearGlide; Datascope Corp, Montvale, NJ),
hich allows venous blood flow to be maintained during harvest.
emographics, preoperative risk factors and medications, and in-
raoperative and postoperative data were prospectively imported
Abbreviations and Acronyms
CABG coronary artery bypass grafting
EVH  endoscopic vein harvest
OCT  optical coherence tomography
SV  saphenous vein
SVG  saphenous vein graft
TEG  thromboelastographynto a relational database. T
260 The Journal of Thoracic and Cardiovascular Surgery ● Novurgical Technique and SVG Handling
ll patients underwent median sternotomy, followed by concurrent
eft internal thoracic artery harvest and EVH. Using either
asoView or ClearGlide system, we initiated EVH by insertion of
conical dissection cannula to create a tunnel around the vein. For
he VasoView device, a seal was created within the tunnel by
nflating a trochar port balloon to less than 5 mL and then CO2 was
nsufflated to a pressure of 10 to 12 mm Hg. With the ClearGlide
VH system, CO2 insufflation was used to facilitate endoscopic
isualization, but without a sealed tunnel (Figure 1). Division of
ranches was performed with bipolar electrocautery set at 20
atts. Proximal SV ligation was performed through a separate stab
ncision. After removal from the leg, the SV was flushed and
tored in a Plasma-Lyte solution (Baxter International, Inc, Deer-
eld, Ill) containing heparin, glyceryl trinitrate, and verapamil.10
iven that all patients underwent off-pump CABG, heparin ad-
inistration was titrated to an activated clotting time greater than
00 seconds and a heparin level greater than 2 IU/mL according to
rotamine titration assay (HMS system; Medtronic, Inc, Minneap-
lis, Minn). Aprotinin was given intraoperatively to selected high-
isk patients according to a previously established protocol.11
erioperative aspirin was used in all patients (325 mg by mouth
aily). Shed mediastinal blood was collected intraoperatively and
etransfused with a cell salvage device (Cobe BRAT 2; CobeCar-
iovascular, Arvada, Colo). Perioperative coagulation was moni-
ored by thromboelastography (TEG 5000; Haemoscope, Niles, Ill)
ctivated by kaolin.
easurement of Intraluminal Clot
ll SVs were imaged intraoperatively after EVH with an imaging
robe (ImageWire; LightLab Imaging, Westford, Mass) intro-
uced into the vein during gentle saline infusion. Residual clot was
dentified within the SV lumen via cross-sectional OCT images
nd distinguished by the characteristic radial signal attenuation
roduced by thrombi as previously described.8,12 Clot distribution
ithin the tract of vein was documented by externally marking the
ocation of the imaging probe, visualized through the vessel wall
y the rotating infrared light at the catheter tip. This information
as used to calculate the portion of vein that contains clot relative
o the total conduit length (ie, “clot fraction”). The volume of clot
ithin each conduit was also calculated off-line with proprietary
oftware (LightLab Imaging). These analyses were performed by a
echnician blinded to group assignment.
So that the diagnosis of intraluminal clot could be confirmed
istologically, biopsy specimens were procured from discarded SV
egments registered to the area of intraluminal clot visualized via
CT imaging. These “image-guided” biopsy specimens were em-
edded and frozen in cutting compound (Tissue-Tek O.C.T., Red-
ing, Calif), then sectioned at 5 m, and stained with hematoxylin
nd eosin.
atency Analysis
VG patency at 1 week was determined by blinded review
f a computed tomographic angiogram (420-ms rotation,
00–150 mL contrast agent intravenously at 5 mL/s) with retro-
pective electrocardiographic gating. Patency was defined as any
ow through the entire graft regardless of the presence of stenosis.
he graft was classified as nonpatent if a stump was seen or if there
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ETas no contrast in an area known by operative report to contain a
raft, a validated definition of postoperative bypass graft failure.13
tatistics
he primary end point of this study was the difference in clot
etween groups as defined by the clot fraction and clot volume,
nalyzed with 1-way analysis of variance and the Bonferroni
ultiple comparison test. Patient and conduit characteristics were
ompared among all 4 groups by a 1-way analysis of variance or
2 test for continuous and categorical variables, respectively. Cor-
elations were sought between potential risk factors for clot for-
ation and clot volume and clot fraction by regression analysis. To
orrect for the multiple comparisons that have been performed on
ur data set regarding SVG patency,14 we defined a P value of 
01 as significant when comparing patency rates. Statistical anal-
sis was performed with the InStat statistical package (GraphPad
oftware, Inc, San Diego, Calif) with the assistance of a biostat-
stician (A.J.).
esults
tudy Characteristics
atient characteristics that might influence the tendency for
enous thrombus formation were similar among the 4 pa-
ient groups (Table 1). The mean length of the SV tract that
as harvested and imaged was 27.4  6.9 cm, whereas the
ength used for the necessary graft(s) was 20.3  7.6 cm
74% of total length used), with no significant differences in
hese lengths noted between the treatment groups. The av-
rage time required for intraoperative OCT scanning was
.6  1.2 minutes per SV. Mean clot volume and fraction
ere less in the grafted portion of SV (7.1  20.1 mm3 and
2% 33%) than in the discarded portion (9.5 17.1 mm3
nd 36%  41%), but these differences did not reach
tatistical significance.
ntraluminal Clot
he ability to diagnose intraluminal clot by OCT imaging
ABLE 1. Potential risk factors for venous clot formation
haracteristic
VasoView unheparinized
control (n  10)
VasoVi
full
ale sex (%) 80
ge (y) 65.0 11.5
ody mass index 30.1 7.7
iabetes (%) 20
moking history (%) 80
reoperative heparin (%) 40
reoperative clopidogrel (%) 20
reoperative aspirin* (%) 80
ntraoperative aprotinin (%) 50
VD (%) 20
reoperative TEG MA† 65.6 6.4
VD, Peripheral vascular disease; TEG MA, maximum amplitude of the thro
f variance and 2). *Patients taking preoperative daily aspirin before hosas confirmed in registered histologic sections (Figure (
The Journal of Thoracic). Clot was detected by OCT in all 10 control SVs (ie,
asoView device without preheparinization), with 80%
f these veins found to have clot strands throughout the
ajority of their lengths. Preheparinization before sealed
O2 EVH (either low or high dose) yielded significant
eductions in clot fraction (Figure 3) and clot volume
Figure 4). Additionally, significant reductions in clot
raction and volume were noted after EVH with an open
O2 insufflation system. When intraluminal clot was
maged within veins from the 3 intervention groups, it
as normally of trivial volume compared with the clot
bserved in the control group. In the control group, both
ge (r  0.66, P  .05) and preoperative TEG maximum
mplitude (r  0.97, P  .0001) were found to signifi-
antly correlate with intraluminal clot volume. None of
he other risk factors for venous thrombus (listed in Table
) were found to have an effect on intraluminal clot
ormation during EVH.
Preheparinization was believed to increase the technical
ifficulty of left internal thoracic artery harvest and EVH,
wing to increased oozing in the surgical field. However,
ntraoperative blood loss and perioperative and postopera-
ive blood product requirements were similar in all patient
roups. Intimal injury as visualized by OCT imaging was an
nusual finding after EVH and almost always confined to
he ostia of branch points. The incidence of these branch
oint tears was similar between groups (VasoView
ystem  13% vs ClearGlide system  10% of SVs with at
east one ostial branch tear; P  not significant). Only one
evere intimal tear was imaged within the procured SV, and
hat occurred after a VasoView harvest. The vast majority of
lot strands (89%) were observed to attach to the vessel wall
t no discrete structure with only a minority attached to
alves (6%), branch points (4%), and focal areas of trauma
eheparinized,
(n  10)
VasoView preheparinized,
low dose (n  10)
ClearGlide
unheparinized (n  10)
0 80 80
 10.6 63.9  12.6 63.4  8.8
 5.7 27.9  4.7 28.3  4.5
0 50 40
0 70 80
0 70 80
0 0 10
0 90 80
0 70 30
0 10 10
 9.9 67.1  7.7 64.0  7.5
lastography trace. P  not significant for all comparisons (1-way analysis
admission.ew pr
dose
8
64.9
29.6
4
7
5
1
8
6
1
63.6
mboe1%).
and Cardiovascular Surgery ● Volume 134, Number 5 1261
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ETVG Patency
our SVGs in the control group were occluded (patency
ate  69%) at 1 week, whereas only 1 SVG was occluded
n the 3 intervention groups (patency rate 97%), but these
igure 1. Sealed versus open CO2 insufflation EVH. The VasoView
VH system (Guidant Corp) (A) uses an inflated balloon to seal the
ncision site while CO2 is constantly insufflated to a pressure of
0 to 12 mm Hg during harvest. In contrast, the ClearGlide EVH
evice (Datascope Corp) (B) does not rely on sealed CO2 insuf-
ation. An open incision allows gas to freely escape from the
arvesting tunnel. Although this modification may make visual-
zation more challenging with the ClearGlide device, it allows for
ore consistent blood flow within the SV during harvest and
pproximates an open harvesting method in this regard.262 The Journal of Thoracic and Cardiovascular Surgery ● Novifferences did not reach statistical significance. The mean
lot volume and fraction in occluded SVGs was 29.7 38.1
m3 and 0.57  0.34, as compared with 6.3  15.7 mm3
nd 0.26  0.31 in patent grafts (P  not significant).
iscussion
lot strands after EVH have been previously described.8
owever, without a practical method for intraoperative im-
ging of conduits, the actual volume and distribution of clot
etained within the SV lumen after flushing has never been
ully appreciated. In this study, we establish that OCT is
ble to accurately identify the incidence and severity of this
roblem, as well as provide the necessary sensitivity for
etecting small changes in the volumes of clot after alter-
tions in standard EVH practice. Because this OCT exam-
nation can be done in real time, intraoperatively, and with
inimal interference in the normal surgical protocol (aver-
ge scan time  4.6 minutes), this method represents an
mportant quality assurance tool for investigating the effec-
iveness of various conduit harvest protocols. We noted that
lot retained within the SV was a universal and specific
nding to EVH with sealed CO2 insufflation in the absence
f heparinization before initiation of the procedure. Use of
pen CO2 insufflation to maintain flow within the SV, or
ystemic administration of heparin before occluding flow
sing a sealed CO2 system, both led to dramatic reductions
n this retained clot. These findings support our hypothesis
hat clot formation during EVH is the result of stagnant
lood that is not anticoagulated being allowed to remain
ithin a collapsed SV.
In assessing preoperative risk factors for clot formation
n the control group, we found both age and the maximum
mplitude of the TEG trace (a measure of platelet function)
o be significantly correlated with intraluminal clot volume.
ur data corroborate previous reports suggesting that the
isk for hypercoagulability is linked to increased age15 and
hat TEG maximum amplitude specifically correlates with
he risk of postoperative deep vein thrombosis.16 Although
Figure 2. Histologic correlation of in-
traluminal clot. Intraluminal clot (ar-
rowheads) is visible as a signal-rich
lobulated mass via OCT (A) and in a
registered histologic section (B). Note
the characteristic radial signal attenu-
ation that the clot produces on OCT
imaging (asterisk).ember 2007
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EThese data suggest that elderly patients with elevated TEG
aximum amplitude are the most likely to benefit from the
nterventions described in this report, the small number of
atients included in this analysis places us at risk for a type
statistical error. Clarification of which patients are at
reatest risk from SV harvest via the VasoView device
ithout preheparinization awaits further study.The Journal of ThoracicPreheparinization did not change blood loss or transfu-
ion requirements, suggesting that it is a benign and effec-
ive method for avoiding clot strands when the VasoView
ystem is used. However, EVH with open CO2 insufflation
ignificantly reduced the volume and length of retained clot
ithin the conduit without the need for anticoagulation
efore the completion of sternotomy and left internal tho-
Figure 3. Clot fraction. Intraluminal
clot was a universal finding in unhe-
parinized control veins with 80% con-
taining clot throughout the majority of
their length. Preheparinziation, using
both full (titrated to activated clotting
time >300 seconds) and low (5000-IU
bolus) doses, was associated with a
significant reduction in overall fraction
of the vein containing clot, with many
veins containing no clot at all. Open
CO2 EVH yielded a similar reduction in
clot fraction without preheparinization.
Figure 4. Clot volume. Preheparinzia-
tion, using both full (titrated to acti-
vated clotting time > 300 seconds)
and low (5000-IU bolus) doses, was
associated with a significant de-
crease in clot volume. Open CO2 EVH
without preheparinization produced
a similar reduction. When clot was
present in preheparinized or open
CO2 EVH veins, it was normally of
trivial volume (B, arrowhead) com-
pared with the substantial volumes
imaged in the unheparinized control
group (A, arrowhead).and Cardiovascular Surgery ● Volume 134, Number 5 1263
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1
ETacic artery takedown. The benefit of this alternative har-
esting system is likely derived by maintaining constant
lood flow within the SV during EVH. It is important to
ote that our group and others17 have found endoscopic
isualization to be more technically challenging with an
pen CO2 insufflation system.
Our study was not appropriately powered to determine
hether intraluminal clot strands predispose to graft failure.
recent study showed that 5-year event-free survival (free-
om from death, myocardial infarction, or recurrent angina)
as not significantly different in patients with SVGs pro-
ured via EVH versus open harvest.18 However, this study
sed an open CO2 EVH system and, as evidenced by our
ndings, cannot be extrapolated to EVH with the VasoView
evice. A meta-analysis based on several small randomized
rials suggested no adverse effect of EVH on angiographic
atency.4 Again, of the 3 trials that comprised the data in
his report, only the trial by Perrault and associates19 used a
losed CO2 insufflation EVH system without prehepariniza-
ion. This trial included only 40 patients and showed a
onsignificant trend toward reduced patency of SVGs har-
ested with a protocol that, as we now know, is prone to
ntraluminal clot formation.
In contrast, the recent PREVENT IV multicenter trial20
as appropriately powered to assess graft patency and used
redominantly closed CO2 insufflation during EVH. Al-
hough not dictated by the protocol or specifically described
n the report, it can be assumed that the timing of heparin
dministration followed the common practice at most cen-
ers, which is to avoid heparinization until after internal
horacic artery (and therefore SV) harvest. In this large
eport, the use of EVH instead of an open technique was an
ndependent predictor of graft failure.5 Endothelial integrity
as been found to be similar by our group and others2,6,7
etween SVs harvested by these 2 techniques. Taken to-
ether, these data strongly suggest that intraluminal clot
trands that are retained after endoscopic procurement may
ave played a causal role in the higher risk of SVG loss after
VH observed in the PREVENT IV study.
Our study has limitations. Group assignment was not
andomized, which increases the risk that bias may have
nfluenced our results. We believe that the impact of any
ias introduced by this study design was minimized because
atient characteristics that would be likely to affect clot
ormation were found to be similar between groups and SV
lot was analyzed by a single technician blinded to group
ssignment. Our study was statistically powered to demon-
trate the effects of changes to the EVH protocol on clot
ormation but not to address the mechanism or pathogenic-
ty of clot formation or the risks of preheparinization. The
esults of this study are most appropriately used as prelim-
nary data to support the design of a randomized trial that
ill provide more definitive conclusions on these issues.
264 The Journal of Thoracic and Cardiovascular Surgery ● NovBy enabling the quantification of this issue as never
efore possible, OCT screening revealed that retained clots
re frequently found within the SV after EVH. Our pilot
ata suggest that heparinization before EVH or use of an
pen CO2 system are benign changes in practice that can
ignificantly improve this complication. Further studies are
equired to determine the pathogenicity of this finding.
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iscussion
r Michael Mack (Dallas, Tex). A paper presented at the Southern
horacic Surgical Association meeting last year analyzed the
REVENT IV trial for graft patency and found that endoscopic
ein harvest was a risk factor for lower graft patency. I think there
s some evidence that this may have some clinical impact, and you
ay have defined the mechanism.
It is always said to be dangerous to go home after a medical
eeting because people change their practices based on what they
eard at the meeting. On the basis of your presentation, I think I would
eriously consider earlier heparinization in patients. Have you seen
ny adverse clinical sequelae from earlier heparinization, such as late
omplications or hematoma of the harvest tunnel?
Dr Brown. We have not seen any complications such as those.
ncreased bleeding is an obvious concern with preheparinization
nd seems to be one of the reasons that people are reluctant to use
t. However, we found no effect of preheparinization on intraop-
rative blood loss volume or perioperative and postoperative trans-
usion requirements. The only potential complication we noted
as that the surgical field was not quite as dry. There was some
ncreased oozing of blood during harvest of the internal thoracic
rtery.
Dr Valavanur Subramanian (New York, NY). I have two
uestions. Did you determine the age of the clot or the type of the
lot in the SVGs? That would be very important for us.
Dr Brown. We are currently trying to assess the morphology of
his intraluminal clot. One intervention that we have also tried is using
issue plasminogen activator to lyse this clot, but this strategy has not
roved very effective at decreasing clot volume. We have previously
ocumented that this intraluminal clot contains platelets, which may
e contributing to the failure of lysis we are observing. Therefore, we
elieve our tissue plasminogen activator incubation solution might
enefit from the incorporation of a glycoprotein IIb/IIIa inhibitor.
bviously, determining the exact morphology of this intraluminalhrombus would be important in this effort. a
The Journal of ThoracicDr Subramanian. The second question concerns infusion of
eparin through the cut end of the vein graft before you do the
VH. Would that be helpful rather than 5000 units?
Dr Brown. That is something we have also considered. The
roblem we encountered with the strategy you describe was that
he vein harvester did not want to be committed to using that
articular section of the vein. However, some other people have
lso suggested that technique, and it really just depends on whether
he surgeon is comfortable doing that.
Dr A. W. Atkinson (Raleigh, NC). I think it is a wonderful
tudy. Interestingly, in our community we have two hospitals and
e have two different techniques for harvesting vein: one is an
pen system, I believe the Ethicon system, and the other is a closed
ystem with CO2 pressure. When we go from one hospital to the
ther, we obviously see more overt and after we harvest the vein
e see more interluminal thrombus. We have actually started
iving preharvest heparin in small doses. It is not a scientific study
t all, but observationally we saw a marked decrease in interlumi-
al thrombus. We are doing the study in a sense just from one
ospital to the other. I really commend you on documenting this
bservation that we have seen.
I had the same thought as Dr Subramanian. Why don’t we just
ake a small incision at the ankle and flush it with heparinized
aline before harvesting to obviate both problems? I think we may
tart to do that until we get it further documented. However, it is
wonderful study with a new technology that we should look at
ith other aspects of vein harvesting.
Do you have any way to identify vein trauma with this tech-
ology or some other technology about intimal damage? It defi-
itely occurs differently with different techniques.
Dr Brown. Thank you. I realize other surgeons have already
egun giving heparin before EVH, and I think one of the
xciting things about OCT is that it has now allowed us to truly
uantitate the efficacy of this strategy for reducing intraluminal
lot burden.
OCT is also very sensitive for detecting intimal damage. It
bviously has much higher resolution than intravascular ultra-
ound, and we are currently using it to determine conduit quality
ntraoperatively, especially in regard to harvesting—related
rauma. Here you can see an intimal tear, and we normally see this
ccur just around branch points. We also use OCT to evaluate
adial arteries, and in those vessels we see some more overt trauma
han in the SV, probably owing to the more friable nature of the
adial.
Dr Atkinson. Do you have further studies planned comparing
arvesting techniques with intimal damage?
Dr Brown. We are conducting studies like this with the radial
rtery. However, it should be noted that we do not see harvesting-
elated trauma very often in the SV after EVH, so our current trials
re assessing only the radial artery.
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